Keri Maher, DO
Medical Oncology · Richmond, VANPI 1407134471
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $89,700 of the $96,111 with a category attached, or 93.3%. Sobi, Inc accounts for 92.5% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2024 at $38,395 and has fallen 53.8% since, to $17,745 in 2025. Among medical oncology clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 49 payments — averaging $1961.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sobi, Inc$89K
- Dova Pharmaceuticals$7K
- Sanofi$135
- Rigel Pharmaceuticals, Inc.$120
- Adaptive Biotechnologies Corporation$64
- Pharmaessentia USA Corporation$22
- plus $19 from 1 others
Across 175 payments — averaging $4255.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$232K
- Karyopharm Therapeutics Inc.$201K
- Helsinn Healthcare SA$95K
- AbbVie$74K
- Incyte Corporation$48K
- AstraZeneca$42K
- plus $52K from 5 others
What the payments were for
- Consulting fees$4,1004%
- Speaking & faculty fees$89,70093%
- Travel & lodging$4660%
- Food & beverage$1,8452%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sobi, Inc | 42 | $88,901 |
| Dova Pharmaceuticals | 2 | $6,850 |
| Sanofi | 1 | $135 |
| Rigel Pharmaceuticals, Inc. | 1 | $120 |
| Adaptive Biotechnologies Corporation | 1 | $64 |
| Pharmaessentia USA Corporation | 1 | $22 |
| Incyte Corporation | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$96,111 in reported general payments places this provider in the 90th percentile of 95 medical oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IclusigPonatinib Hcl | 23 | $521,390 |
| TibsovoIvosidenib | 13 | $372,314 |
| VenclextaVenetoclax | 79 | $170,937 |
| GleevecImatinib Mesylate | 12 | $59,165 |
| Posaconazole | 41 | $35,999 |
| EliquisApixaban | 22 | $12,910 |
| Voriconazole | 19 | $8,426 |
| Acyclovir | 135 | $3,371 |
| Ondansetron Hcl | 27 | $1,335 |
| Cyclosporine ModifiedCyclosporine, Modified | 13 | $1,162 |
| Levofloxacin | 67 | $1,005 |
| Fluconazole | 19 | $637 |
| Pantoprazole Sodium | 18 | $439 |
| Hydroxyurea | 15 | $270 |
| Prochlorperazine Maleate | 21 | $222 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Richmond
- John McCartyRichmond$97K
- Khalid MatinRichmond$16K
- Janakiraman SubramanianFairfax$562K
- Alexander SpiraFairfax$533K
- Robert DreicerCharlottesville$296K
- Roy BeveridgeFairfax$216K
- Kathleen HarndenFairfax$195K
- Jeanny Aragon-ChingFalls Church$194K
- Nagla Abdel KarimFairfax$131K
- Ryan GentzlerCharlottesville$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.